Scadden David 4

What Happened David Scadden, a director of Editas Medicine, was granted a derivative award on June 17, 2026: an option-like award covering 51,700 shares reported at $0.00 (no cash exchanged). The filing lists the transaction as an award/grant (code A) and reports $0 total value on the Form 4; a footnote states the option vests in full on June 17, 2027. This is a compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026.
• Transaction type/code: Award/Grant (Derivative) — reported price $0.00, reported total $0.
• Shares involved: 51,700 shares (option award); vests in full on June 17, 2027 (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: "This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027."
• Timeliness: Filing date is five days after the transaction; review the full Form 4 for any timeliness flag or explanation.

Context This was a derivative award (an option-style grant) as part of compensation for a director — no exercise, sale, or cash purchase occurred. Such grants are common for executives and directors and do not by themselves indicate a buy or sell signal; they primarily reflect compensation arrangements and future compensation exposure pending vesting.